Novo Nordisk's next-generation obesity drug CagriSema failed to meet weight loss expectations in a late-stage trial, missing the mark set by Eli Lilly's Zepbound. This trial miss may impact the company's stock price and future prospects for the drug. The outcome could also affect the competitive landscape in the obesity treatment market.